Takeda’s revenue climbs by 14.1% in Q1 FY2024
Earnings per share saw an uptick to Y61 - a 5.6% increase from Y58 in Q1 FY2023.
01 August 2024
01 August 2024
Earnings per share saw an uptick to Y61 - a 5.6% increase from Y58 in Q1 FY2023.
FibroGen’s pancreatic cancer therapy, pamrevlumab, failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.
AbCellera is entitled to research payments and downstream milestone payments from Lilly.
The industry is seeking to scale up and satisfy demand for diabetes and obesity treatments that are now chronically in shortage.
In the intent-to-treat cohort, IMNN-001 plus chemotherapy offered a median 11.1-month increase in overall survival versus chemotherapy alone.
The FDA has set a PDUFA target action date of 30 January 2025 for Vertex’s acute pain treatment therapy, which is a non-opioid alternative.
Avicenna will receive an upfront fee and research funding based on the success of compounds developed under the deal.
Zanubrutinib can be administered as once or twice-daily capsules at home.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.